Comparison of the Serum Brain-derived Neurotrophic Factor (BDNF) Between Fibromyalgia and Nociceptive Pain Groups; and Effect of Duloxetine on the BDNF Level

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2022 May 3

PMID 35501732

Authors

Ali Bidari

Banafsheh Ghavidel-Parsa

Faeze Gharibpoor

Affiliations

Soon will be listed here.

Abstract

Background: The primary objective was to compare the serum brain-derived neurotrophic factor (BDNF) level in the patients with two types of pain: fibromyalgia (FM) and non-FM nociceptive pain (non-FM NP). The secondary objective was to investigate the effect of duloxetine on serum BDNF in FM patients and assess the direction of BDNF changes' relation to clinical parameters' alterations.

Methods: This is a study on 73 patients (50 FM and 23 non-FM chronic non-inflammatory pain patients). Serum BDNF was first compared between both groups. Patients with FM, then prospectively, underwent standardized FM treatment with duloxetine maximized to 60 mg/day. The Revised Fibromyalgia Impact Questionnaire (FIQR), Short-Form Health Survey (SF-12), pain visualized analog scale (pain VAS), Beck Depression Inventory-II (BDI-II), polysymptomatic distress scale (PSD) and serum BDNF were measured and compared at baseline and 4 weeks after treatment in FM group.

Results: The mean of adjusted BDNF level in the FM group had no significant difference than the non-FM NP group ((5293.5 ± 2676.3 vs. 6136.3 ± 4037.6; P value = 0.77). Using linear mixed model, we showed that duloxetine reduced BDNF level significantly in FM patients, even after adjusting for depression, pain and severity of the disease (P < 0.01). The FIQR, BDI-II, PSD, and pain VAS improved significantly after duloxetine treatment.

Conclusions: Non-significant BDNF level difference between FM and non-FM nociceptive pain suggested that peripheral BDNF is not a pathophysiological feature of FM. The decreased BDNF level parallel with improvement of PSD/pain scores after duloxetine treatment indicates BDNF alteration in the pain modulation process, regardless of cause and effect.

Citing Articles

Brain-Derived Neurotrophic Factor (BDNF) as a Marker of Physical Exercise or Activity Effectiveness in Fatigue, Pain, Depression, and Sleep Disturbances: A Scoping Review.

Lukkahatai N, Ong I, Benjasirisan C, Saligan L Biomedicines. 2025; 13(2).

PMID: 40002745 PMC: 11853410. DOI: 10.3390/biomedicines13020332.

The Role of the Brain-Derived Neurotrophic Factor in Chronic Pain: Links to Central Sensitization and Neuroinflammation.

Xiong H, Hendrix J, Schabrun S, Wyns A, Van Campenhout J, Nijs J Biomolecules. 2024; 14(1).

PMID: 38254671 PMC: 10813479. DOI: 10.3390/biom14010071.

Brain-derived neurotrophic factor in fibromyalgia: A systematic review and meta-analysis of its role as a potential biomarker.

Behnoush A, Khalaji A, Khanmohammadi S, Alehossein P, Saeedian B, Shobeiri P PLoS One. 2023; 18(12):e0296103.

PMID: 38127937 PMC: 10734974. DOI: 10.1371/journal.pone.0296103.

Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions.

Favretti M, Iannuccelli C, Di Franco M Int J Mol Sci. 2023; 24(13).

PMID: 37445618 PMC: 10341963. DOI: 10.3390/ijms241310443.

What Do We Know about Nociplastic Pain?.

Buldys K, Gornicki T, Kalka D, Szuster E, Biernikiewicz M, Markuszewski L Healthcare (Basel). 2023; 11(12).

PMID: 37372912 PMC: 10298569. DOI: 10.3390/healthcare11121794.

References

Bidari A, Ghavidel-Parsa B, Amir Maafi A, Montazeri A, Ghalehbaghi B, Hassankhani A . Validation of fibromyalgia survey questionnaire and polysymptomatic distress scale in a Persian population. Rheumatol Int. 2015; 35(12):2013-9. DOI: 10.1007/s00296-015-3340-z. View

Miranda M, Morici J, Zanoni M, Bekinschtein P . Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front Cell Neurosci. 2019; 13:363. PMC: 6692714. DOI: 10.3389/fncel.2019.00363. View

Castren E, Kojima M . Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis. 2016; 97(Pt B):119-126. DOI: 10.1016/j.nbd.2016.07.010. View

Forsgren S, Grimsholm O, Dalen T, Rantapaa-Dahlqvist S . Measurements in the Blood of BDNF for RA Patients and in Response to Anti-TNF Treatment Help Us to Clarify the Magnitude of Centrally Related Pain and to Explain the Relief of This Pain upon Treatment. Int J Inflam. 2011; 2011:650685. PMC: 3132632. DOI: 10.4061/2011/650685. View

Doan L, Manders T, Wang J . Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast. 2015; 2015:504691. PMC: 4355564. DOI: 10.1155/2015/504691. View

Kosek E, Cohen M, Baron R, Gebhart G, Mico J, Rice A . Do we need a third mechanistic descriptor for chronic pain states?. Pain. 2016; 157(7):1382-1386. DOI: 10.1097/j.pain.0000000000000507. View

Jablochkova A, Backryd E, Kosek E, Mannerkorpi K, Ernberg M, Gerdle B . Unaltered low nerve growth factor and high brain-derived neurotrophic factor levels in plasma from patients with fibromyalgia after a 15-week progressive resistance exercise. J Rehabil Med. 2019; 51(10):779-787. DOI: 10.2340/16501977-2593. View

Nijs J, Meeus M, Versijpt J, Moens M, Bos I, Knaepen K . Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target?. Expert Opin Ther Targets. 2014; 19(4):565-76. DOI: 10.1517/14728222.2014.994506. View

Emon M, Das R, Nishuty N, Qusar M, Bhuiyan M, Islam M . Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. BMC Res Notes. 2020; 13(1):83. PMC: 7035767. DOI: 10.1186/s13104-020-04952-3. View

10.

Lee J, Duan W, Mattson M . Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem. 2002; 82(6):1367-75. DOI: 10.1046/j.1471-4159.2002.01085.x. View

11.

Arumugam V, John V, Augustine N, Jacob T, Joy S, Sen S . The impact of antidepressant treatment on brain-derived neurotrophic factor level: An evidence-based approach through systematic review and meta-analysis. Indian J Pharmacol. 2017; 49(3):236-242. PMC: 5637134. DOI: 10.4103/ijp.IJP_700_16. View

12.

Sairanen M, Lucas G, Ernfors P, Castren M, Castren E . Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci. 2005; 25(5):1089-94. PMC: 6725966. DOI: 10.1523/JNEUROSCI.3741-04.2005. View

13.

Trajkovska V, Marcussen A, Vinberg M, Hartvig P, Aznar S, Knudsen G . Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull. 2007; 73(1-3):143-9. DOI: 10.1016/j.brainresbull.2007.03.009. View

14.

Haas L, Portela L, Bohmer A, Oses J, Lara D . Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res. 2010; 35(5):830-4. DOI: 10.1007/s11064-010-0129-z. View

15.

Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C . Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003; 54(1):70-5. DOI: 10.1016/s0006-3223(03)00181-1. View

16.

Tsilioni I, Russell I, Stewart J, Gleason R, Theoharides T . Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. J Pharmacol Exp Ther. 2016; 356(3):664-72. PMC: 4767394. DOI: 10.1124/jpet.115.230060. View

17.

Sikandar S, Minett M, Millet Q, Santana-Varela S, Lau J, Wood J . Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain. Brain. 2018; 141(4):1028-1039. PMC: 5888992. DOI: 10.1093/brain/awy009. View

18.

Baumeister D, Eich W, Saft S, Geisel O, Hellweg R, Finn A . No evidence for altered plasma NGF and BDNF levels in fibromyalgia patients. Sci Rep. 2019; 9(1):13667. PMC: 6754372. DOI: 10.1038/s41598-019-49403-7. View

19.

Sarchielli P, Mancini M, Floridi A, Coppola F, Rossi C, Nardi K . Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain. 2007; 8(9):737-45. DOI: 10.1016/j.jpain.2007.05.002. View

20.

Montazeri A, Vahdaninia M, Mousavi S, Omidvari S . The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity. BMC Public Health. 2009; 9:341. PMC: 2749829. DOI: 10.1186/1471-2458-9-341. View